Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for joining us and welcome to the Nate Farmer First Quarter 2026 Business Update and Financial Results. After today's remarks, we will host a question and answer session. If you'd like to ask a question, please press Start 1 on your telephone keypad to raise your hand. I will now hand the conference over to Stephanie Kornan, Vice President of Investor Relations, Communication and Commercial Strategy at Nate Farmer. Please go ahead. Good morning and good afternoon, everyone. Thank you for joining us for EnateParma's Q1 2026 Business Update and Financial Results Conference Call. The press release and today's presentation are both available on the IR section of our website. Before we begin, I would like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially. To briefly cover today's agenda, our CEO, Jonathan Dickinson, will begin with a strategic overview and outlook. Sonia Quarantino, our chief medical officer, and Yanis Morel, our chief operating officer and I, will then provide updates on Lactamab, IPH4502, and next-generation ADCs, as well as AstraZeneca partner program, including Monalizumab and IPH5201. Jonathan will then return with closing remarks. Frederic Lombard, our CFO, will join us for the Q&A. With that, I will now hand it over to Jonathan. Thank you, Stephanie. Good morning to those joining from the US and good afternoon to our European participants. Turning to slide five. We continue to execute against our strategy, which is focused on our three priority assets, with discipline, and we're pleased with the strong progress we are seeing today. Starting with lakutamab,...